UA77596C2 - Albumin containing fraction having a reduced prekallikrein activator content and fraction obtained - Google Patents

Albumin containing fraction having a reduced prekallikrein activator content and fraction obtained Download PDF

Info

Publication number: UA77596C2
Authority: UA; Ukraine
Prior art keywords: fraction; albumin; solution; filter; stage
Prior art date: 2002-11-25

Application number

UAA200506246A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Octapharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-25

Filing date

2003-11-25

Publication date

2006-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32337993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA77596(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-11-25 Application filed by Octapharma Ag filed Critical Octapharma Ag

2006-12-15 Publication of UA77596C2 publication Critical patent/UA77596C2/uk

Links

102000009027 Albumins Human genes 0.000 title claims abstract description 34
108010088751 Albumins Proteins 0.000 title claims abstract description 34
108010071241 Factor XIIa Proteins 0.000 title claims abstract description 24
238000005194 fractionation Methods 0.000 claims abstract description 3
238000010438 heat treatment Methods 0.000 claims abstract description 3
238000000034 method Methods 0.000 claims description 15
238000009928 pasteurization Methods 0.000 claims description 13
238000011534 incubation Methods 0.000 claims description 7
238000004806 packaging method and process Methods 0.000 claims description 5
238000011084 recovery Methods 0.000 claims description 3
238000012876 topography Methods 0.000 claims 1
238000011049 filling Methods 0.000 abstract description 5
238000004519 manufacturing process Methods 0.000 abstract 1
239000000243 solution Substances 0.000 description 48
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
230000001954 sterilising effect Effects 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
239000008215 water for injection Substances 0.000 description 18
102000004169 proteins and genes Human genes 0.000 description 17
108090000623 proteins and genes Proteins 0.000 description 17
239000012528 membrane Substances 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
238000001914 filtration Methods 0.000 description 11
239000000758 substrate Substances 0.000 description 11
238000011026 diafiltration Methods 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
239000003814 drug Substances 0.000 description 9
229940079593 drug Drugs 0.000 description 9
238000000108 ultra-filtration Methods 0.000 description 8
239000000872 buffer Substances 0.000 description 7
230000000694 effects Effects 0.000 description 7
108090000113 Plasma Kallikrein Proteins 0.000 description 6
230000007547 defect Effects 0.000 description 6
239000000203 mixture Substances 0.000 description 6
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
239000011148 porous material Substances 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
239000011734 sodium Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000012141 concentrate Substances 0.000 description 4
238000001802 infusion Methods 0.000 description 4
230000000007 visual effect Effects 0.000 description 4
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 3
108060005987 Kallikrein Proteins 0.000 description 3
102000001399 Kallikrein Human genes 0.000 description 3
239000000654 additive Substances 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
238000005429 filling process Methods 0.000 description 3
239000012535 impurity Substances 0.000 description 3
229960002446 octanoic acid Drugs 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
239000008174 sterile solution Substances 0.000 description 3
238000004659 sterilization and disinfection Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003593 chromogenic compound Substances 0.000 description 2
239000013068 control sample Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000008520 organization Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000036454 renin-angiotensin system Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
229960005480 sodium caprylate Drugs 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000013026 undiluted sample Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UAA200506246A 2002-11-25 2003-11-25 Albumin containing fraction having a reduced prekallikrein activator content and fraction obtained UA77596C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02026165		2002-11-25
PCT/EP2003/013239 WO2004047859A2 (en)	2002-11-25	2003-11-25	Prekallikrein depleted plasma derived albumin fraction

Publications (1)

Publication Number	Publication Date
UA77596C2 true UA77596C2 (en)	2006-12-15

Family

ID=32337993

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200506246A UA77596C2 (en)	2002-11-25	2003-11-25	Albumin containing fraction having a reduced prekallikrein activator content and fraction obtained

Country Status (23)

Country	Link
US (1)	US7700732B2 (de)
EP (1)	EP1565207B1 (de)
JP (1)	JP4532282B2 (de)
KR (1)	KR101077651B1 (de)
CN (1)	CN100364609C (de)
AT (1)	ATE322907T1 (de)
AU (1)	AU2003292109B2 (de)
BR (1)	BR0316563A (de)
CA (1)	CA2506848C (de)
DE (1)	DE60304603T2 (de)
DK (1)	DK1565207T3 (de)
ES (1)	ES2261977T3 (de)
IL (1)	IL168506A (de)
MX (1)	MXPA05005328A (de)
NO (1)	NO330216B1 (de)
PL (1)	PL375539A1 (de)
PT (1)	PT1565207E (de)
RS (1)	RS20050401A (de)
RU (1)	RU2321421C2 (de)
SI (1)	SI1565207T1 (de)
UA (1)	UA77596C2 (de)
WO (1)	WO2004047859A2 (de)
ZA (1)	ZA200504202B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2221817B1 (es)	2004-07-26	2005-10-01	Probitas Pharma, S.A.	"soluciones de albumina humana terapeutica con baja actividad del activador de precalicreina (pka) y procedimiento de obtencion de las mismas".
ES2294976B1 (es) *	2007-11-12	2008-12-16	Grifols, S.A.	"procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
SE1050124A1 (sv)	2010-02-08	2011-08-09	Linkoping Biocontrols Ab	Stabil lösning
GB201317458D0 (en) *	2013-10-02	2013-11-13	Spd Swiss Prec Diagnostics Gmbh	Improved pregnancy test device and method
CN107216383A (zh) *	2017-07-13	2017-09-29	同路生物制药有限公司	一种人血白蛋白的制备方法及该人血白蛋白

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2190436B1 (de) *	1972-07-05	1975-06-20	Merieux Inst
US4378346A (en)	1979-08-15	1983-03-29	Tankersley Donald L	Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
US4251510A (en)	1979-08-15	1981-02-17	Cutter Laboratories, Inc.	Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
US4440679A (en) *	1980-03-05	1984-04-03	Cutter Laboratories, Inc.	Pasteurized therapeutically active protein compositions
EP0035204B2 (de) *	1980-03-05	1991-05-22	Miles Inc.	Pasteurisierte therapeutisch aktive Proteinzusammensetzungen
US4391801A (en)	1981-10-29	1983-07-05	Cutter Laboratories, Inc.	Plasma protein fraction substantially free of acetate ions
AT376367B (de)	1983-03-16	1984-11-12	Immuno Ag	Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
SU1212416A1 (ru) *	1984-04-03	1986-02-23	Научно-Исследовательский Институт Гематологии И Переливания Крови Им.Проф.Р.О.Еоляна	Способ выделени альбумина из плазмы крови
AT391810B (de)	1988-02-26	1990-12-10	Immuno Ag	Verwendung von chymotrypsin zum unwirksammachen des praekallikrein-aktivators
JP3554796B2 (ja) *	1988-10-31	2004-08-18	三菱ウェルファーマ株式会社	アルブミン製剤及びその製造方法
RU2007423C1 (ru) *	1991-06-04	1994-02-15	Институт биофизики клетки РАН	Способ очистки сывороточного альбумина
US5919907A (en) *	1997-12-22	1999-07-06	Shanbrom Technologies Llc	Preparation and utilization of a novel sterile albumin
US6693173B2 (en)	2000-12-26	2004-02-17	Alpha Therapeutic Corporation	Method to remove citrate and aluminum from proteins

2003
- 2003-11-25 BR BR0316563-9A patent/BR0316563A/pt not_active IP Right Cessation
- 2003-11-25 RU RU2005119987/15A patent/RU2321421C2/ru not_active IP Right Cessation
- 2003-11-25 DK DK03767649T patent/DK1565207T3/da active
- 2003-11-25 AT AT03767649T patent/ATE322907T1/de active
- 2003-11-25 SI SI200330277T patent/SI1565207T1/sl unknown
- 2003-11-25 CA CA2506848A patent/CA2506848C/en not_active Expired - Fee Related
- 2003-11-25 MX MXPA05005328A patent/MXPA05005328A/es active IP Right Grant
- 2003-11-25 EP EP03767649A patent/EP1565207B1/de not_active Revoked
- 2003-11-25 UA UAA200506246A patent/UA77596C2/uk unknown
- 2003-11-25 PT PT03767649T patent/PT1565207E/pt unknown
- 2003-11-25 DE DE60304603T patent/DE60304603T2/de not_active Expired - Lifetime
- 2003-11-25 RS YUP-2005/0401A patent/RS20050401A/sr unknown
- 2003-11-25 US US10/533,160 patent/US7700732B2/en not_active Expired - Fee Related
- 2003-11-25 JP JP2004554458A patent/JP4532282B2/ja not_active Expired - Fee Related
- 2003-11-25 WO PCT/EP2003/013239 patent/WO2004047859A2/en not_active Ceased
- 2003-11-25 PL PL03375539A patent/PL375539A1/xx unknown
- 2003-11-25 CN CNB2003801041314A patent/CN100364609C/zh not_active Expired - Fee Related
- 2003-11-25 AU AU2003292109A patent/AU2003292109B2/en not_active Ceased
- 2003-11-25 ES ES03767649T patent/ES2261977T3/es not_active Expired - Lifetime
- 2003-11-25 KR KR1020057008932A patent/KR101077651B1/ko not_active Expired - Fee Related
2005
- 2005-05-10 IL IL168506A patent/IL168506A/en not_active IP Right Cessation
- 2005-05-24 ZA ZA200504202A patent/ZA200504202B/en unknown
- 2005-05-26 NO NO20052550A patent/NO330216B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR101077651B1 (ko)	2011-10-27
RU2321421C2 (ru)	2008-04-10
BR0316563A (pt)	2005-10-04
ES2261977T3 (es)	2006-11-16
PT1565207E (pt)	2006-07-31
CN100364609C (zh)	2008-01-30
AU2003292109A1 (en)	2004-06-18
DE60304603D1 (de)	2006-05-24
CA2506848C (en)	2012-09-11
SI1565207T1 (sl)	2006-08-31
ZA200504202B (en)	2006-02-22
NO20052550D0 (no)	2005-05-26
ATE322907T1 (de)	2006-04-15
IL168506A (en)	2010-11-30
NO20052550L (no)	2005-08-12
WO2004047859A3 (en)	2004-08-05
RU2005119987A (ru)	2006-01-20
EP1565207A2 (de)	2005-08-24
DE60304603T2 (de)	2007-02-15
CN1717249A (zh)	2006-01-04
EP1565207B1 (de)	2006-04-12
AU2003292109B2 (en)	2009-02-05
JP2006518705A (ja)	2006-08-17
KR20050085043A (ko)	2005-08-29
CA2506848A1 (en)	2004-06-10
US20060100419A1 (en)	2006-05-11
RS20050401A (sr)	2007-06-04
JP4532282B2 (ja)	2010-08-25
US7700732B2 (en)	2010-04-20
NO330216B1 (no)	2011-03-07
PL375539A1 (en)	2005-11-28
DK1565207T3 (da)	2006-08-14
MXPA05005328A (es)	2005-08-16
WO2004047859A2 (en)	2004-06-10

Publication	Publication Date	Title
JP3701028B2 (ja)	2005-09-28	高純度フォンビルブラント因子の入手方法
US5122373A (en)	1992-06-16	Immunoglobulin-g-containing fraction
JP5357391B2 (ja)	2013-12-04	液状形態及び凍結乾燥形態の免疫グロブリンｇ組成物用安定化配合物
HU180816B (en)	1983-04-29	Process for producing composition from human nlood plasma for improving agglutination of blood
JPS63192724A (ja)	1988-08-10	ｒ−グロブリンの液状製剤
JP2010529997A (ja)	2010-09-02	安定化トロンビン組成物
TWI554283B (zh)	2016-10-21	經由熱處理獲得ＩｇＧ組成物的方法
UA77596C2 (en)	2006-12-15	Albumin containing fraction having a reduced prekallikrein activator content and fraction obtained
KR950010321B1 (ko)	1995-09-14	인간 트롬빈 제제의 가열처리방법
JPH04346934A (ja)	1992-12-02	γ−グロブリンの液状製剤
US20140155498A1 (en)	2014-06-05	Method of Manufacture of Stable Liquid Coagulation Factors
US20100193440A1 (en)	2010-08-05	Use of a chromatography substrate for reducing the amount of adamts13 in a solution derived from plasma
RU2457248C2 (ru)	2012-07-27	Способ промышленного получения тромбина
US20250281530A1 (en)	2025-09-11	Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration
RU2768656C1 (ru)	2022-03-24	Противовирусное средство в жидкой форме и способ его приготовления
RU2814332C1 (ru)	2024-02-28	Способ криоконсервации промежуточного продукта фактора viii свертывания крови
RU2155069C1 (ru)	2000-08-27	Способ получения иммуноглобулина для внутривенного введения и его варианты
Friedman et al.	2001	Preparation and clinical use of plasma and plasma fractions
KR102372105B1 (ko)	2022-03-07	면역글로블린의 제조방법
Gammelgaard et al.	1997	Aluminium in human albumin solutions
MXPA97000617A (en)	1997-12-01	Human therapeutic albumin with low capacity for the fixation of alumi